{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:58:29Z","timestamp":1785466709150,"version":"3.56.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12328-026-02330-3","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:39:04Z","timestamp":1776335944000},"page":"869-875","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Successful retreatment with glecaprevir\/pibrentasvir after sofosbuvir\/velpatasvir failure in a patient with hepatitis C-related decompensated cirrhosis complicated by hepatocellular carcinoma"],"prefix":"10.1007","volume":"19","author":[{"given":"Minami","family":"Ogura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Naganuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nakajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otone","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanae","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0224-7093","authenticated-orcid":false,"given":"Satoru","family":"Kakizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"2330_CR1","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(23)01320-X","volume":"402","author":"M Martinello","year":"2023","unstructured":"Martinello M, Solomon SS, Terrault NA, et al. Hepatitis C. Lancet. 2023;402:1085\u201396.","journal-title":"Lancet"},{"key":"2330_CR2","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","volume":"373","author":"MP Curry","year":"2015","unstructured":"Curry MP, O\u2019Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618\u201328.","journal-title":"N Engl J Med"},{"key":"2330_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00535-018-1503-x","volume":"54","author":"T Takehara","year":"2019","unstructured":"Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 2019;54:87\u201395.","journal-title":"J Gastroenterol"},{"key":"2330_CR4","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1053\/j.gastro.2024.08.018","volume":"167","author":"M Premkumar","year":"2024","unstructured":"Premkumar M, Dhiman RK, Duseja A, Mehtani R, Taneja S, Gupta E, et al. Recompensation of chronic hepatitis C-related decompensated cirrhosis following direct-acting antiviral therapy: prospective cohort study from a hepatitis C virus elimination program. Gastroenterology. 2024;167:1429\u201345.","journal-title":"Gastroenterology"},{"key":"2330_CR5","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s40121-020-00329-y","volume":"9","author":"M Atsukawa","year":"2020","unstructured":"Atsukawa M, Tsubota A, Kondo C, Toyoda H, Nakamuta M, Takaguchi K, et al. Real-world clinical application of 12-week sofosbuvir\/velpatasvir treatment for decompensated cirrhotic patients with genotype 1 and 2: a prospective, multicenter study. Infect Dis Ther. 2020;9:851\u201366.","journal-title":"Infect Dis Ther"},{"key":"2330_CR6","unstructured":"The American Association for the Study of Liver Diseases and Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. Available at: https:\/\/www.hcvguidelines.org. Accessed January 8, 2026."},{"key":"2330_CR7","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"European Association for the Study of the Liver","year":"2020","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73:1170\u2013218.","journal-title":"J Hepatol"},{"key":"2330_CR8","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1053\/j.gastro.2019.02.046","volume":"156","author":"AG Singal","year":"2019","unstructured":"Singal AG, Lim JK, Kanwal F. AGA clinical practice update on interaction between oral direct-acting antivirals for chronic Hepatitis C infection and hepatocellular carcinoma: expert review. Gastroenterology. 2019;156:2149\u201357.","journal-title":"Gastroenterology"},{"key":"2330_CR9","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/hepr.13503","volume":"50","author":"Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology","year":"2020","unstructured":"Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res. 2020;50:791\u2013816.","journal-title":"Hepatol Res"},{"key":"2330_CR10","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/hepr.13501","volume":"50","author":"Y Asahina","year":"2020","unstructured":"Asahina Y, Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. JSH guidelines for the management of Hepatitis C virus infection, 2019 update; Protective effect of antiviral therapy against hepatocarcinogenesis. Hepatol Res. 2020;50:775\u201390.","journal-title":"Hepatol Res"},{"key":"2330_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S2468-1253(16)30009-7","volume":"1","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Stepanova M, Charlton M, et al. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol. 2016;1:122\u201332.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2330_CR12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.cgh.2016.10.037","volume":"15","author":"ZM Younossi","year":"2017","unstructured":"Younossi ZM, Stepanova M, Feld J, et al. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. Clin Gastroenterol Hepatol. 2017;15:421\u201330.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2330_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/hepr.13576","volume":"51","author":"Y Takaoka","year":"2021","unstructured":"Takaoka Y, Miura K, Morimoto N, et al. Real-world efficacy and safety of 12-week sofosbuvir\/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection. Hepatol Res. 2021;51:51\u201361.","journal-title":"Hepatol Res"},{"key":"2330_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00535-020-01733-4","volume":"56","author":"Y Tahata","year":"2021","unstructured":"Tahata Y, Hikita H, Mochida S, et al. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. J Gastroenterol. 2021;56:67\u201377.","journal-title":"J Gastroenterol"},{"key":"2330_CR15","doi-asserted-by":"publisher","first-page":"6247","DOI":"10.1002\/jmv.27157","volume":"93","author":"T Tada","year":"2021","unstructured":"Tada T, Kurosaki M, Nakamura S, et al. Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Med Virol. 2021;93:6247\u201356.","journal-title":"J Med Virol"},{"key":"2330_CR16","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1111\/hepr.13555","volume":"50","author":"K Ohya","year":"2020","unstructured":"Ohya K, Imamura M, Teraoka Y, et al. Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis. Hepatol Res. 2020;50:1234\u201343.","journal-title":"Hepatol Res"},{"key":"2330_CR17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/hepr.13868","volume":"53","author":"Y Tahata","year":"2023","unstructured":"Tahata Y, Sakamori R, Maesaka K, et al. Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis. Hepatol Res. 2023;53:301\u201311.","journal-title":"Hepatol Res"},{"key":"2330_CR18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.35772\/ghm.2021.01083","volume":"3","author":"Y Tahata","year":"2021","unstructured":"Tahata Y, Sakamori R, Takehara T. Treatment progress and expansion in Japan: from interferon to direct-acting antiviral. Glob Health Med. 2021;3:321\u201334.","journal-title":"Glob Health Med"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02330-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-026-02330-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02330-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:04:07Z","timestamp":1785463447000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-026-02330-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2330"],"URL":"https:\/\/doi.org\/10.1007\/s12328-026-02330-3","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Atsushi Naganuma has received research funding AstraZeneca and CureApp. Takeshi Hatanaka has received research funding from CureApp. Satoru Kakizaki has received lecture fees from AbbVie. The remaining authors have no conflicts to report.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures followed were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","label":"Human and animal participants","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for the publication of this report.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}